Self-nanomicellizing solid dispersion is a new formulation that combines the advantages of solid dispersion and nanomicelles strategies to increase drug oral bioavailability. The strategy involves utilizing a suitable carrier to create a solid dispersion that self-assembles into nanomicelles when it comes into contact with gastrointestinal fluids. Rebaudioside A is a steviol glycoside that has been reported to possess nano carrier-like characteristics by being self-assembled into nanomicelles in aqueous solutions. Canagliflozin is a novel sodium-glucose cotransporter-2 inhibitor approved for treating patients with type 2 diabetes. Its oral administration is associated with variable and poor absorption, owing primarily to insolubility in aqueous media. This work aimed to develop canagliflozin self-nanomicellizing solid dispersion systems to overcome its pharmaceutical limitation and enhance oral bioavailability. The solvent evaporation method was selected to prepare a self-nanomicellizing solid dispersion system of canagliflozin. Rebaudioside A was chosen as a nanocarrier after screening several polymers for their ability to improve the solubility of canagliflozin by phase solubility study. The optimized formulations were characterized by solid-state analysis, dissolution studies,  particle size distribution, and  TEM. The study demonstrates that the self-nanomicellizing solid dispersion of canagliflozin, based on Rebaudioside A (FR5), has a 69.7 nm spherical particle size, stable distribution upon 20-fold  dilution, and improved aqueous solubility by over 753.5-fold due to nanomicellization, as determined through scanning calorimetry, X-ray diffraction, dynamic light scattering, and transmission electron microscopy. Moreover, there is a significant enhancement of dissolution rate compared with the physical mixture (PM) and pure drugs, as indicated by higher values of f₁ and lower values of f₂, which are obtained. The optimized formula of canagliflozin self-nanomicellizing SD (FR5) dissolved well after 30 minutes and demonstrated higher dissolution efficiency (DE) than the intact canagliflozin and physical mixture. The DE% parameter confirms these findings (DE₃₀,FR5 = 70.34%, DE₃₀,PM = 21.91%, and DE₃₀,pure drug = 18.28%.  Fourier transform infrared spectroscopy reveals mild interactions between the drug and the excipient due to hydrogen bonding, favoring the formation of a stable solid dispersion system with negligible chemical interactions. The study indicates that optimized canagliflozin self-nanomicellizing sold dispersion systems using rebaudioside A are promising methods for improving oral bioavailability.